Latest Erythropoietin Stories
THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago.
SAN DIEGO, May 13, 2011 /PRNewswire/ -- ViaCyte, Inc., a preclinical cell therapy company focused on diabetes, today announced the appointment of Anthony ("Tony") Gringeri as Chief Development Officer. Dr.
Intravenous administration of epoetin alfa, a product that stimulates red blood cell production, to patients with heart attack who were undergoing percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), did not provide reduction in the size of the heart muscle involved and was associated with higher rates of adverse cardiovascular events.
SHIRLEY, N.Y., May 3, 2011 /PRNewswire/ -- American Regent announces that, effective immediately, it has resumed the shipment of VenoferÂ® (iron sucrose injection, USP).
New product from Red X Labs designed to increase both testosterone and to increase red blood cell production is now available in the USA without a prescription. Denver, CO (PRWEB) April 23, 2011 Most bodybuilders think of EPO (erythropoietin) as an endurance drug used by long distance runners and cyclists, and it is.
NES-ZIONA, Israel, March 14, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today announced that it is relocating its corporate office and R&D facility to a new, significantly larger building located a short distance from its current site in the Weizmann Science Park in Nes Ziona, Israel.
NES-ZIONA, Israel, Feb. 14, 2011 /PRNewswire/ -- PROLOR Biotech, Inc.
In two recent studies, researchers have identified two functional variants in the inosine triphosphatase (ITPA) gene that protect patients with hepatitis C virus (HCV) against anemia brought on by antiviral treatment.
NES-ZIONA, Israel, Jan. 18, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd.
Patients with diabetes, kidney disease and anemia who donâ€™t respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death.
- Withering but not falling off, as a blossom that persists on a twig after flowering.